Key facts
- This page summarizes Yarlagadda S. Babu's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Nov 2022, 15:19.
Yarlagadda S. Babu - 14 Nov 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)
- Reporting relationship
- Chief Discovery Officer
- Issuer ticker
- BCRX
- Reported as of
- 14 Nov 2022
- Net transaction value
- -$295,428
- SEC form
- 4
- Accepted by SEC
- 16 Nov 2022, 15:19:59 UTC
- Prior SEC filing
- 09 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alane P. Barnes, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Yarlagadda S. Babu filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 16 Nov 2022.
Change
- Previous filing in this sequence was filed on 09 Mar 2022.
- Current net transaction value: -$295,428.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCRX
transaction
Common Stock
Options Exercise
- Transaction value
- $71,000
- Shares
- +50,000
- Change %
- +22%
- Price
- $1.42*
- Shares after
- 280,056
- Date
- 14 Nov 2022
- Ownership
- Direct
BCRX
transaction
Common Stock
Options Exercise
- Transaction value
- $71,000
- Shares
- +50,000
- Change %
- +18%
- Price
- $1.42*
- Shares after
- 330,056
- Date
- 14 Nov 2022
- Ownership
- Direct
BCRX
transaction
Common Stock
Sale
- Transaction value
- $437,428
- Shares
- -31,515
- Change %
- -9.5%
- Price
- $13.88
- Shares after
- 298,541
- Date
- 14 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCRX
transaction
Derivative
Emp. Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $1.42
- Footnotes
- F2
BCRX
transaction
Derivative
Emp. Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $1.42
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $13.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Footnote F2
Annual Employee Option Grant became exercisable in four equal annual installments, beginning on this date.
Footnote F3
Retention Employee Stock Option became exercisable in two equal annual installments, beginning on this date.